van Schaik: Acquired MassArray, 67 muts, 5 genes, sensitivie and inbetween ddPCR and cobas WRT price #ampeurope2018

4:38am May 2nd 2018 via Twitter Web Client

Agena workshop Ron van Schaik (Erasmus Univ NE): Shows 200-400 yearly requests for cfDNA #ampeurope2018 Reviews ddP… https://t.co/OwXoQiFhqu

4:38am May 2nd 2018 via Twitter Web Client

Q: NeoAg prediction? Figdor: #ampeurope2018 DNA / RNA seq, ID potential ones, not as high as expected, differ bet. pts.

3:32am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Provocative but TMB is not ready for clinical use; MMRD tumors 40% resp rate

3:30am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Emerging indications: melanoma, lung, renal cell, Hodgkin, H&N, bladder, Merkel cell, MMR-D

3:29am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Q about standardization of TMB, assoc'd with PFS not OS. 'A mess' TMB cost is 5x-10x of PDL1… https://t.co/ZVyEMjsUvs

3:27am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Q: is it ready for pt care? How reprod? Only one company? Large amt of sample. PD-L1 access - 34%/58% TMB avail

3:26am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 CheckMate 227: Nivo plus Ipi at >10 mut/MB in NSCLC, PFS 43% vs 13% at 12mos. 'A provocative marker'

3:23am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Shows ORR by coding mutations (shown yesterday too) https://t.co/dhqMA0ts8n

3:22am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Mut load correlates with poor clinical outcome to anti-PD-1 in NSCLC. '16 https://t.co/DI0FIQF31L

3:20am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Largest database of its kind, worldwide. https://t.co/soi0zSX7kh

3:17am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Biopsy: WGS 110x, RNA-seq too. Have 2.8k samples of metastatic tumors, with Rx data, avail for research

3:16am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Edwin Cuppen: national scale WGS, a nationwide effort (Hartwig Fndn). Blood (serum, WBC); 38x WGS.

3:15am May 2nd 2018 via Twitter Web Client

Horlings: #ampeurope2018 Ultra-high muts correlate with MMR and POL-E. Looking at hypermutated trinucleotide context - and clustering

3:14am May 2nd 2018 via Twitter Web Client

Horlings: #ampeurope2018 WGS of 560 br ca samples, looking for MMR-D, found 12. looking at MLH1, MSH2, MSH6, PMS2 status, cp to Circos plots

3:09am May 2nd 2018 via Twitter Web Client

Horlings: #ampeurope2018 MMR-D and PD-1 blockade: Le in NEJM '15, Science '17. 'A pan-tumor predictive marker for I-O'

3:05am May 2nd 2018 via Twitter Web Client

Horlings: #ampeurope2018 Slightly higher 9.9 mut/MB in pediatric ca. 17% are above 10, 1% above 100. On the highest: Kidney, Prostate

3:03am May 2nd 2018 via Twitter Web Client

Horlings: #ampeurope2018 81K tumors of 315 cancer-rel genes in '17 https://t.co/4eIkuGgoho Shows threshold of hypermut. 9 mut/MB

3:02am May 2nd 2018 via Twitter Web Client

Horlings: #ampeurope2018 A spiderweb of 7 different parameters - from TMB, lymphyocytic ct, immune infilt, PD-L1 st… https://t.co/Ybmp1It0MT

2:58am May 2nd 2018 via Twitter Web Client

Horlings: #ampeurope2018 TIL Rx - exfused, expanded, infused with IL-2; shows photos of a case where dramatic lesions disappearing

2:55am May 2nd 2018 via Twitter Web Client

Horlings: #ampeurope2018 Form '11 https://t.co/DGfZwBzIyL to now: 3y OS of StgIV melanoma chart shown

2:53am May 2nd 2018 via Twitter Web Client

Hugo Horlings (Netherlands Cancer Inst Amsterdams, The Netherlands) #ampeurope2018 Molecular Basis of Cancer Immuno… https://t.co/XUZKHP7sen

2:52am May 2nd 2018 via Twitter Web Client

Q: Polymer have a half-life? Figdor: #ampeurope2018 Unknown as of yet, biodistribution studies in mice ongoing.

2:45am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Limited in the Ag's for solid tumors that we have; only two. We can hope that can be expanded.

2:43am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Anticipates all patients will be sequenced; then HLA neoantigens can be predicted. CD4 response impt, will get better

2:40am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Used Vectra multimodal staining, scanning the entire tumor, and det CD3, CD8, CD45, FoxP3, CD45ro, GrzB, tumor

2:30am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 It is the numberof CD3+ T-cells for primary melanoma predicts surv after DC-based I-O https://t.co/TNSEJUETyN

2:30am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 These polymers act like flexible springs, with antibodies and derivatized w/biotin. Shows docked Abs image

2:23am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Uses Toll-Like Receptor. good resp w/both OVA Ag and TLR ligand. Is working with a flexible polymer

2:22am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Targets dendritic cells (DCs) with PLGA biogradable polymer, and antibodies etc. '11 https://t.co/prTlDcgNK5

2:18am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Key milestone, '15 Niv for NSCLC, Pembro for PD-L1+ NSCLC. And a balance of dendritic cells… https://t.co/qkobiS5Vxr

2:10am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Points out in 1970 Morton described marked tumor regression, with BCG injection w/melanoma (https://t.co/zbnvcUg4yG)

2:10am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Illust the complexity of the innate and adaptive immune system: an ensemble, interactions, different in each pt

2:07am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Major difficulty: only a fx of pts respond. How will we predict who will respond - the challenge for the next decade

2:06am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 Shows a K-M curve from people with lymphopenia: less immune cells, do worse '13 https://t.co/EcQH5g6Dcj

2:05am May 2nd 2018 via Twitter Web Client

Figdor: #ampeurope2018 As a novel treatment modality: Immune surveillance in '11 Science https://t.co/HsJtiD3qXR

2:04am May 2nd 2018 via Twitter Web Client

Carl Figdor (Nijmegen NE): #ampeurope2018 Immunotherapies in cancer, 21st century vaccines

2:03am May 2nd 2018 via Twitter Web Client

Q: Classification w/different IDH1 mut type? Nikiforova: #ampeurope2018 The complexity of interpretation; why each… https://t.co/H6Na068boD

12:10pm May 1st 2018 via Twitter Web Client

Q (Andrea F) 59 samples is a 'big number' can you have 2-3 in same sample? Nikiforova: #ampeurope2018 Can include a… https://t.co/e3DmBexaOC

12:05pm May 1st 2018 via Twitter Web Client

Nikiforova: #ampeurope2018 Credits @AMPath staff @Robyn_Temple and Mrudulla for all their hard work!

12:04pm May 1st 2018 via Twitter Web Client

Nikiforova: #ampeurope2018 WHO Grade I/II/III det by IDH1/2, then TP53 mut/loss and ATRX, then RB1. Shows K-M and difference in outcomes

11:59am May 1st 2018 via Twitter Web Client

Nikiforova: #ampeurope2018 Categorization of brain tumors - she calls GliaSeq. Shows complex example, with RB1 copy… https://t.co/6CNdcKETxE

11:56am May 1st 2018 via Twitter Web Client

Nikiforova: #ampeurope2018 Reviews Tiers 1 through 4 (strong clin sig through benign). (Note: See pg 2 of this Mary… https://t.co/GaI9WdC7ti

11:54am May 1st 2018 via Twitter Web Client

Nikiforova: #ampeurope2018 For reporting: https://t.co/G22oEoj6GC Ex: 45yo F thyroid nodule, TERT and NRAS vars. Se… https://t.co/3dpJKpgFNU

11:47am May 1st 2018 via Twitter Web Client

Nikiforova: #ampeurope2018 shows busy slide, for their v3 ThyroSeq https://t.co/iUqjo0wb2d Prospective double-blin… https://t.co/qztxq82OLQ

11:45am May 1st 2018 via Twitter Web Client

Nikiforova: #ampeurope2018 Not only reporting vars but explanation to physician what it means.

11:41am May 1st 2018 via Twitter Web Client

Nikiforova: #ampeurope2018 Also gene exp, SNVs, indels. 112 genes, 12K hotspots, 120 gene fusion types, preoperative test.

11:41am May 1st 2018 via Twitter Web Client

Nikiforova: #ampeurope2018 Give example of Thyroid nodules, after FNA to eliminate 'interdeminate' after pathology.… https://t.co/WKZQe2SMrO

11:40am May 1st 2018 via Twitter Web Client